Empli03 for chronic pain, ready for GMP manufacturing for the clinical study

2021-12-22 08:05

Emplicure AB has developed the formulation of Empli03 to be used for GMP manufacturing for the first clinical study. Agreement has been signed with Quotient Sciences, UK, who will be responsible for the manufacturing and will also perform the first pharmacokinetic study.

"We have achieved one of our milestones in the development of an opiod product for treatment of chronic pain. With an even and stabile release profile, and with properties that limit abuse, Empli03 can contribute to a safer medical treatment", says Torbjörn W. Larsson, CEO of Emplicure


Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

For more information, please contact:

Torbjörn W. Larsson
Phone: +46 (0)70 747 65 99
Email: twl@emplicure.com

Anna-Lena Nicolson
CFO, Investor Relations
Phone: +46 (0)72 33 68 68
Email: aln@emplicure.com

The following documents can be retrieved from beQuoted

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at www.emplicure.com

Do you want to know more?